Latest news

Adalvo has received DCP approval for Azelastine/Fluticasone nasal spray, strengthening its respiratory portfolio and meeting key market needs.  This approval aligns with  Adalvo’s clearly defined IP pathway, leveraging a complex, difficult-to-develop...

Adalvo has submitted the DCP for Palbociclib film-coated tablets, reinforcing its commitment to expanding its oncology portfolio. Approval is expected in November 2025.  Supported by Adalvo’s focused IP strategy, this submission is...

In recognition of World Diabetes Day, Adalvo highlights its diabetes portfolio, built with a focus on rapid market access and a strong IP strategy.  Our diabetes basket spans a wide range...

Adalvo has received DCP approval for Dapagliflozin film-coated tablets ahead of the standard 210-day timeline, allowing strategic preparation for a Day-1 launch. Backed by a strong IP strategy, Adalvo is...

Adalvo announces the successful multi-country launch of Lisdexamfetamine. To our knowledge, Adalvo was one of the first to introduce this differentiated product in key European markets, showcasing our industry-leading launch...

Adalvo and Myonex announced today the expansion of their existing agreement, under which Myonex is the exclusive provider of Adalvo products for clinical trial use globally. Both parties have now...

Adalvo will submit the DCP for Palbociclib Film-coated Tablets in November 2024.  This submission will strengthen Adalvo’s oncology portfolio, which is backed by our robust IP strategy and aims to guarantee rapid market access....

Adalvo has been recognised with two prestigious awards at the 2024 Global Generics & Biosimilars Bulletin Awards: Business Development of the Year and Value Added Medicine of the Year.  The Business Development...

Adalvo reports significant progress in the development of Fidaxomicin Film Coated Tablets, with the dossier on track for global submission by the end of 2024.  As we gear up for the...

At Adalvo we are driven by our commitment to our partner network, dedicated to making a meaningful impact and improving patient lives globally. We are proud to share that Adalvo has been...

Adalvo has submitted its DCP filing for Teduglutide on Day-1 following the expiry of Data Exclusivity. Teduglutide has been developed for the treatment of short bowel syndrome (SBS), a rare condition...

Adalvo has recently signed a licensing and supply agreement with Dr. Reddy’s Laboratories to commercialise Dalbavancin Ready-to-Dilute (RTD) in the United States. Under this strategic agreement, Adalvo will license the exclusive...

Adalvo announces the successful DCP approval for Ethinylestradiol/Drospirenone 0.03mg /3mg tablets.  Based on the reference brand Yasmin, Ethinylestradiol/Drospirenone has been developed in collaboration with one of our strategic partners. The INN is a...

Adalvo has successfully launched Dimethyl Fumarate (DMF) across various markets, serving over 20 partners on three continents. Dimethyl Fumarate 120mg and 240mg hard capsules have been developed based on the reference brand Tecfidera,...

Adalvo has successfully launched the first and only Pregabalin Extended-Release (ER) tablets in Europe. This differentiated product has been introduced in two major European markets, Germany and Spain, through partnerships...

Adalvo secures successful DCP approval for Mirabegron 50mg prolonged-release tablets.  Developed based on the reference brand Betmiga prolonged-release tablets, Mirabegron is indicated for the treatment of urgency, increased micturition frequency, and/or...

Adalvo successfully launched the first and only Desmopressin Orally Disintegrating Tablets (ODT) in Europe in March 2024.  Developed based on the reference brand Minirin Melt, Desmopressin ODT is indicated for the...